Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;116(2):207-216.
doi: 10.1111/vox.13002. Epub 2020 Sep 30.

10-year analysis of human immunodeficiency virus incidence in first-time and repeat donors in Brazil

Sheila de Oliveira Garcia Mateos  1   2 , Liliana Preiss  3 , Thelma T Gonçalez  4 , Claudia Di Lorenzo Oliveira  5 , Eduard Grebe  4   6 , Clara Di Germanio  4 , Mars Stone  4 , Luiz Amorim Filho  2 , Anna Bárbara Carneiro Proietti  7 , Andre Rolim Belisario  7 , Cesar de Almeida-Neto  8   9 , Alfredo Mendrone-Junior  8 , Paula Loureiro  10   11 , Michael P Busch  4   6 , Brian Custer  4   6 , Ester Cerdeira Sabino  1   12 ; Recipient Epidemiology, Donor Evaluation Study (REDS-III) International Component Brazil
Affiliations

10-year analysis of human immunodeficiency virus incidence in first-time and repeat donors in Brazil

Sheila de Oliveira Garcia Mateos et al. Vox Sang. 2021 Feb.

Abstract

Background and objectives: Incidence in first-time and repeat blood donors is an important measure of transfusion-transmitted HIV infection (TT-HIV) risk. This study assessed HIV incidence over time at four large blood centres in Brazil.

Materials and methods: Donations were screened and confirmed using serological assays for HIV from 2007 to 2016, and additionally screened by nucleic acid testing from 2011 forward. Limiting antigen (LAg) avidity testing was conducted on HIV seroreactive samples from first-time donors to classify whether an infection was recently acquired. We calculated incidence in first-time donors using the mean duration of recent infection and in repeat donors using classical methods. Time and demographic trends were assessed using Poisson regression.

Results: Over the 10-year period, HIV incidence in first-time donors was highest in Recife (45·1/100 000 person-years (105 py)) followed by São Paulo (32·2/105 py) and then Belo Horizonte (23·3/105 py), and in repeat donors was highest in Recife (33·2/105 py), Belo Horizonte (27·5/105 py) and São Paulo (17·0/105 py). Results from Rio de Janeiro were available from 2013 to 2016 with incidence in first-time donors of 35·9/105 py and repeat donors from 2011 to 2016 of 29·2/105 py. Incidence varied by other donor demographics. When incidence was considered in 2-year intervals, no significant trend was evident. Overall residual risk of TT-HIV was 5·46 and 7·41 per million units of pRBC and FFP transfused, respectively.

Conclusion: HIV incidence in both first-time and repeat donors varied by region in Brazil. Clear secular trends were not evident.

Keywords: blood safety; donors; residual risk estimation; serological testing; transfusion- transmissible infections.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The authors have disclosed no conflicts of interest.

Figures

Figure 1.
Figure 1.
HIV Incidence per 100,000 Person Years and 95% Confidence Interval by Time Interval and Blood Center for First-Time (FTD) and Repeat Donors (RD), 2007 to 2016
Figure 2.
Figure 2.
Comparison of HIV Incidence per 100,000 Person Years and 95% Confidence Interval by Age and Blood Center for First-Time (FTD) and Repeat Donors (RD), 2007 to 2016
See this image and copyright information in PMC

References

    1. WHO: Blood safety and availability. World Health Organization. 2019.
    1. Brambilla DJ, Busch MP, Dodd RY, et al.: A comparison of methods for estimating the incidence of human immunodeficiency virus infection in repeat blood donors. Transfusion 2017; 57: 823–31. - PMC - PubMed
    1. Sedia Biosciences Corporate. Sedia HIV-1 LAg-Avidity EIA; in Corporation SB, (ed). USA, 2018.
    1. ANVISA: Agência Nacional de Vigilância Sanitária. ANVISA, PRODUÇÃO HEMOTERÁPICA, Hemoprod 2017. 2018.
    1. Carneiro-Proietti AB, Sabino EC, Leao S, et al.: Human T-lymphotropic virus type 1 and type 2 seroprevalence, incidence, and residual transfusion risk among blood donors in Brazil during 2007–2009. AIDS Res Hum Retroviruses 2012; 28: 1265–72. - PMC - PubMed